Journal of controlled release : official journal of the Controlled Release Society · 2025
An antioxidant metal-organic framework with functional coatings for oral anti-TNF-α antibody delivery in inflammatory bowel disease treatment.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Cheng, Guilbaud Léo, Marotti Valentina, Zhang Wunan, Domingues Inês, Yagoubi Hafsa, Vints Katlijn, Xu Yining, Beloqui Ana
Аннотация
Oral biomacromolecule delivery is considered a promising alternative for patients who must receive long-term invasive injections, providing better patient compliance. However, it still faces great challenges due to the harsh gastrointestinal environment, including instability and poor intestinal absorption. Here, we report an antioxidant moiety (manganese ion, Mn4+)-assembled metal-organic framework (MOF) presenting functionalized coatings consisting of an inner layer of hyaluronic acid-polyethylene glycol and an outer layer of Eudragit® S100 for enhanced colon-targeted delivery of an anti-mouse tumor necrosis factor-alpha (TNF-α) antibody via oral route. The developed anti-TNF-α antibody-MOF system presented gastric resistance, enhanced targeting of the inflamed intestine, and antioxidant activity. In acute inflammatory bowel disease (IBD) models, the therapeutic effect of the oral anti-TNF-α antibody-MOF system was similar, or even better, than that of intravenous injections at the same antibody dose, with superior antioxidant and mucosal healing capacities. We also demonstrated that in a chronic murine colitis model, the oral anti-TNF-α antibody-MOF system significantly reduced the pathological features of the disease, especially the levels of proinflammatory factors and oxidation markers, which did not differ significantly from those in healthy mice. Overall, this study provides a promising strategy for the oral delivery of antibodies in IBD treatment.